Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends
    Meeting Abstract

    Rosenthal, K.; Galsky, M. D.; Milowsky, M. I.; Petrylak, D. P.; Rosenberg, J. E.; Obholz, K.; Plimack, E. R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Hullings, M.; Carbone, E.; Barnett, E.; Sutton, R.; Jendrisak, A.; Landers, M. A.; Wang, Y.; Dittamore, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Meeting Abstract

    Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC)
    Meeting Abstract

    Petrylak, D. P.; Rosenberg, J. E.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E. M.; Melhem-Bertrandt, A.; Powles, T.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Time to PSA nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy
    Meeting Abstract

    Pike, L. R. G.; Wu, J.; Chen, M. H.; Loffredo, M.; Renshaw, A. A.; Pfail, J.; Kantoff, P. W.; D'Amico, A. V.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Rini, B. I.; Escudier, B.; Murphy, D.; Wang, P.; Tarazi, J. C.; Motzer, R. J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Rosenberg, J. E.; Sridhar, S. S.; Zhang, J.; Smith, D. C.; Ruether, J. D.; Flaig, T. W.; Baranda, J. C.; Lang, J. M.; Plimack, E. R.; Sangha, R. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
    Meeting Abstract

    Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA
    Meeting Abstract

    Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save